Daré Bioscience (NASDAQ:DARE – Get Free Report) issued its quarterly earnings results on Monday. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.02, Zacks reports.
Daré Bioscience Stock Performance
NASDAQ:DARE traded up $0.01 during trading hours on Monday, hitting $2.89. The company’s stock had a trading volume of 20,264 shares, compared to its average volume of 45,555. Daré Bioscience has a 52-week low of $2.67 and a 52-week high of $7.56. The business’s 50-day moving average is $3.07 and its two-hundred day moving average is $3.29. The company has a market capitalization of $25.14 million, a PE ratio of -4.89 and a beta of 1.38.
Analysts Set New Price Targets
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Daré Bioscience in a report on Tuesday, December 17th.
Daré Bioscience Company Profile
Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.
Featured Articles
- Five stocks we like better than Daré Bioscience
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- 3 Buyable Stocks With Solid Bottoms Ready to Rebound
- Options Trading – Understanding Strike Price
- Advantage+ Shopping: Meta’s Fast Growing $20 Billion AI-Ads Star
- Stock Market Upgrades: What Are They?
- Robotaxi News: What Tesla and Lyft Headlines Mean for Shares
Receive News & Ratings for Daré Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daré Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
